|
Market Closed -
Nasdaq
16:00:00 2026-11-06 EST
|
5-day change | 1st Jan Change | ||
| 132.37 USD | +1.98% |
|
-8.35% | -27.52% |
| 11-03 | Axsome Therapeutics Could Achieve Earnings in 2027 Amid Growing Auvelity Revenue, RBC Says | MT |
| 11-03 | UBS Adjusts Axsome Therapeutics Price Target to $239 From $256, Maintains Buy Rating | MT |
| Market Cap | 6.96B 6.24B 5.71B 5.21B 9.82B 655B 10.13B 68.79B 27.43B 349B 26.13B 25.57B 1,102B | P/E 2026 * |
-52.8x | P/E 2027 * | 36.3x |
|---|---|---|---|---|---|
| Enterprise Value | 6.81B 6.11B 5.58B 5.1B 9.6B 640B 9.91B 67.3B 26.84B 342B 25.57B 25.02B 1,079B | EV / Sales 2026 * |
7.14x | EV / Sales 2027 * | 4.49x |
| Free-Float |
84.76% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| AXSM | Delayed | |
CBOE
| AXSM | Real-time | |
|
Tradegate
| 19X | Real-time | |
|
London S.E.
| 0HKF | Delayed | |
|
Boerse Muenchen
| 19X | Real-time | |
|
Xetra
| 19X | Delayed | |
|
Deutsche Boerse AG
| 19X | Delayed | |
|
Börse Stuttgart
| 19X | Delayed | |
|
Borsa Italiana
| 1AXSM | End-of-day quote |
Last Transcript: Axsome Therapeutics, Inc.
| 1 day | +1.98% | ||
| 1 week | -8.35% | ||
| Current month | -8.35% | ||
| 1 month | -24.07% | ||
| 3 months | -37.01% | ||
| 6 months | -40.54% | ||
| Current year | -27.52% |
| 1 week | 123 |  | 145.5 |
| 1 month | 123 | | 172.28 |
| Current year | 123 | | 260.19 |
| 1 year | 123 | | 260.19 |
| 3 years | 55.02 | | 260.19 |
| 5 years | 20.63 | | 260.19 |
| 10 years | 1.94 | | 260.19 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 57 | 2012-01-11 | |
Nick Pizzie
DFI | Director of Finance/CFO | 51 | 2018-05-15 |
Mark Jacobson
COO | Chief Operating Officer | 42 | 2014-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 57 | 2012-01-11 | |
Roger Jeffs
BRD | Director/Board Member | 64 | 2014-11-30 |
Mark Coleman
BRD | Director/Board Member | 58 | 2014-11-30 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/3/26 | Exercice | Chief Operating Officer | 30,000 | 0.0573% | ||
| 8/6/26 | Exercice | Chief Executive Officer | 13,980 | 0.0272% | ||
| 7/1/26 | Exercice | Chief Executive Officer | 148,998 | 0.2895% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.98% | -8.35% | -5.05% | +112.06% | 6.83B | |
| -0.79% | -4.48% | +44.44% | +127.49% | 1,216B | |
| +1.43% | +1.11% | +47.73% | +82.08% | 656B | |
| +1.07% | -1.21% | +32.99% | +106.31% | 509B | |
| -0.36% | -3.25% | +47.17% | +64.58% | 384B | |
| -0.14% | -1.87% | +71.05% | +40.63% | 362B | |
| -0.78% | -0.52% | +30.57% | +57.98% | 311B | |
| -0.80% | -0.21% | +8.54% | +35.56% | 293B | |
| +0.03% | -1.20% | +45.89% | +68.76% | 249B | |
| -0.41% | -2.22% | +35.24% | +105.68% | 208B | |
| Average | +0.12% | -1.29% | +35.86% | +80.11% | 419.46B | |
| Weighted average by Cap. | -0.05% | -1.22% | +42.12% | +88.39% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 954M 856M 782M 714M 1.34B 89.67B 1.39B 9.43B 3.76B 47.85B 3.58B 3.5B 151B | 1.46B 1.31B 1.19B 1.09B 2.05B 137B 2.12B 14.38B 5.73B 72.98B 5.46B 5.34B 230B |
| Net income | -129M -115M -105M -96.23M -181M -12.09B -187M -1.27B -507M -6.45B -483M -472M -20.36B | 160M 144M 131M 120M 226M 15.07B 233M 1.58B 632M 8.04B 602M 589M 25.39B |
| Net Debt | -151M -135M -124M -113M -213M -14.17B -219M -1.49B -594M -7.56B -566M -554M -23.87B | -423M -380M -347M -317M -597M -39.8B -616M -4.18B -1.67B -21.24B -1.59B -1.56B -67.05B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-06 | US$132.37 | +1.98% | 718,345 |
| 26-11-05 | US$129.80 | -5.26% | 1,109,525 |
| 26-11-04 | US$137.00 | -1.87% | 1,034,195 |
| 26-11-03 | US$139.61 | +2.65% | 1,679,569 |
| 26-11-02 | US$136.01 | -5.83% | 2,717,813 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AXSM Stock
Select your edition
All financial news and data tailored to specific country editions
